Spero Therapeutics Inc. (SPRO) is approaching a key regulatory moment, with the FDA set to rule on Tebipenem HBr on June 18, 2026. The drug, developed as an oral carbapenem antibiotic, is being reviewed for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis—conditions that often require hospital-based IV therapy.
Tebipenem pivoxil hydrobromide is designed to offer a potent oral alternative for patients who currently rely on intravenous carbapenem, a shift that could ease hospital burden and improve access to treatment as antibiotic resistance continues to rise. Background: Prior FDA Rejection and Resubmission
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.